Skip to main navigation Skip to search Skip to main content

A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer

  • Strickland, Andrew (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA Reference Number: HREC-16-0000-431A
Monash Health HREC Ref: HREC/16/MonH/183
StatusFinished
Effective start/end date11/01/19 → 10/01/24

Clinical Trial Phase

  • Phase III (a & b)